Who are Niacin ER/Simvastatin Tablets's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/niacin-er-simvastatin-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Niacin ER/Simvastatin Tablets — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Niacin ER/Simvastatin Tablets (Niacin ER/Simvastatin Tablets) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination lipid-modifying agent (statin + niacin). Area: Cardiovascular.

phase 3 Combination lipid-modifying agent (statin + niacin) HMG-CoA reductase (simvastatin); GPR109A and DGAT2 (niacin) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Niacin ER/Simvastatin Tablets (Niacin ER/Simvastatin Tablets) — Abbott. Niacin ER/Simvastatin combines extended-release niacin (which increases HDL and lowers triglycerides) with simvastatin (a statin that inhibits HMG-CoA reductase to lower LDL cholesterol).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Niacin ER/Simvastatin Tablets TARGET	Niacin ER/Simvastatin Tablets	Abbott	phase 3	Combination lipid-modifying agent (statin + niacin)	HMG-CoA reductase (simvastatin); GPR109A and DGAT2 (niacin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination lipid-modifying agent (statin + niacin) class)

Abbott · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Niacin ER/Simvastatin Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/niacin-er-simvastatin-tablets. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab